New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
Merck will showcase results in innovative solutions in HIV treatment and prevention
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
Subscribe To Our Newsletter & Stay Updated
